Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Full Year 2024 Results Key Financial Results Revenue: US$179.3m (up 55% from ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $55 from $49 and keeps a Buy rating on the ...

Lamar County Sheriff Danny Rigel has documented 40 years of his law enforcement career in a binder. Most officers would use ...

B. Riley raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $24 from $20 and keeps a Neutral rating on the shares following the ...

On March 6, 2025, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a company specializing in pharmaceutical preparations with a market capitalization of $347 million and impressive revenue growth of 55% ...

Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Rigel Pharmaceuticals ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to ...

On March 6, 2025, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a company specializing in pharmaceutical preparations with a market capitalization of $347 million and impressive revenue growth of 55% over ...